Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) EBITDA Margin (2020 - 2025)

Tango Therapeutics has reported EBITDA Margin over the past 6 years, most recently at 26.15% for Q3 2025.

  • Quarterly results put EBITDA Margin at 26.15% for Q3 2025, up 30941.0% from a year ago — trailing twelve months through Dec 2025 was 34.2% (up 30261.0% YoY), and the annual figure for FY2025 was 163.03%, up 14635.0%.
  • EBITDA Margin for Q3 2025 was 26.15% at Tango Therapeutics, up from 1287.87% in the prior quarter.
  • Over the last five years, EBITDA Margin for TNGX hit a ceiling of 26.15% in Q3 2025 and a floor of 1287.87% in Q2 2025.
  • Median EBITDA Margin over the past 5 years was 427.15% (2022), compared with a mean of 426.89%.
  • Biggest five-year swings in EBITDA Margin: soared 30979bps in 2023 and later crashed -113918bps in 2025.
  • Tango Therapeutics' EBITDA Margin stood at 398.9% in 2021, then decreased by -9bps to 435.33% in 2022, then dropped by -26bps to 550.47% in 2023, then crashed by -81bps to 993.68% in 2024, then skyrocketed by 103bps to 26.15% in 2025.
  • The last three reported values for EBITDA Margin were 26.15% (Q3 2025), 1287.87% (Q2 2025), and 788.76% (Q1 2025) per Business Quant data.